To date, two monoclonal antibodies targeting either IL-6 (Siltuximab) or the IL-6R are approved for the treatment of the autoimmune Castleman disease [14] and different forms of arthritis (Tocilizumab) [15] or rheumatoid arthritis (Sarilumab) [16,17,18]. Here, IL6R is linked to rheumatoid arthritis.